NCT00181597View on ClinicalTrials.gov

Trilostane for Androgen-Independent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Prostate CancerProstate Adenocarcinoma
Interventions
DRUG

Trilostane

Taken orally once a day for three days then twice daily thereafter.

DRUG

Hydrocortisone

Taken orally with trilostane.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00181597 - Trilostane for Androgen-Independent Prostate Cancer | Biotech Hunter | Biotech Hunter